NERV
Minerva Neurosciences, Inc.
Next earnings Aug 12, 2026 · consensus $-0.12 EPS
Last earnings -1.3% on 2026-05-05
$4.37
▲ +6.33%$4.37▲ +146.89%
over 1Y
L $1.63EODHDH $8.07
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+6.3%
1W-6.2%
1M-16.9%
3M-29.3%
YTD+11.5%
1Y+146.9%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity -1.66x).
Minerva Neurosciences, Inc. shows $0.00 in FY2024 revenue.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$45.4M | -$25.2M | -$23.1M | -$21.8M | -$15.1M |
| Net income | -$49.9M | -$32.1M | -$30.0M | $1.44M | -$293M |
| Diluted EPS | -$9.35 | -$6.01 | -$4.61 | $0.19 | -$34.67 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$107M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-155.2%
FCF yield-7.2%
Quality & risk
ROIC (est.)—
Free cash flow-$13.5M
Total debt—
Net cash$82.3M
Altman Z-Score-8.88 distress
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+518.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗4Period ending 2026-06-032026-06-05open ↗8-KPeriod ending 2026-06-032026-06-04open ↗8-KPeriod ending 2026-05-272026-05-27open ↗424B5Filing2026-05-27open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Minerva Neurosciences, Inc. (NERV) a buy?
- NERV currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.66x).
- What is Minerva Neurosciences, Inc.'s quality score?
- NERV scores 18.999999999999996/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001598646, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 7:24:48 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.